Plasma Protein Therapeutics Market Size, Share, Trends, Growth Outlook

Plasma Protein Therapeutics Market is estimated to increase at a growth rate of 6.8% CAGR over the forecast period from 2024 to 2030.

The global Plasma Protein Therapeutics Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Albumin, Immunoglobulin, Plasma-derived factor VIII, Others), By Application (Hemophilia, Primary immunodeficiency disorder (PID), Idiopathic thrombocytopenic purpura (ITP), Others).

An introduction to Plasma Protein Therapeutics Market in 2024

Offering life-saving therapies derived from human plasma, the Plasma Protein Therapeutics Market provides plasma-derived and recombinant protein products for the treatment of various medical conditions, including immunodeficiency disorders, hemophilia, autoimmune diseases, and neurological disorders. Plasma protein therapeutics include immunoglobulins, albumin, clotting factors, and other protein-based therapies manufactured from human plasma or produced using recombinant DNA technology. This market plays a critical role in providing essential therapies to patients with rare and life-threatening conditions, with factors such as increasing prevalence of chronic diseases, advancements in protein purification and biotechnology, and expanding indications driving its growth.

Plasma Protein Therapeutics market Trend: Increasing Adoption of Immunoglobulin Therapies

A significant trend in the Plasma Protein Therapeutics market is the rising adoption of immunoglobulin therapies for treating various autoimmune and immunodeficiency disorders. Immunoglobulins, derived from plasma proteins, are in high demand due to their efficacy in managing conditions such as primary immunodeficiency diseases, autoimmune neuropathies, and inflammatory disorders. This trend reflects the growing recognition of plasma-derived therapies as essential treatment options, driving market growth and innovation in the development of novel immunoglobulin products.

Plasma Protein Therapeutics market Driver: Rising Prevalence of Chronic Diseases

A key driver in the Plasma Protein Therapeutics market is the increasing prevalence of chronic diseases worldwide. Chronic conditions such as immunodeficiency disorders, hemophilia, and autoimmune diseases require long-term therapeutic interventions to manage symptoms and improve patients' quality of life. Plasma protein therapeutics, including immunoglobulins, clotting factors, and albumin, play a crucial role in treating these conditions by providing essential proteins and antibodies that the body lacks, driving demand for plasma-derived therapies and fueling market expansion.

Plasma Protein Therapeutics market Opportunity: Expansion of Plasma Collection and Fractionation Capacity

An enticing opportunity in the Plasma Protein Therapeutics market lies in the expansion of plasma collection and fractionation capacity to meet growing demand. With increasing demand for plasma-derived therapies, there is a need to enhance plasma collection infrastructure, expand donor recruitment efforts, and invest in fractionation facilities to process plasma into therapeutic products efficiently. Companies that invest in expanding their plasma collection and fractionation capabilities can capitalize on the growing Market Opportunity, address supply chain challenges, and ensure a sustainable and reliable source of plasma-derived therapies for patients worldwide.

Plasma Protein Therapeutics Market Market Segmentation

By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Plasma Protein Therapeutics Market Companies

ADMA Biologics Inc
Arthrex Inc
Baxter
Bio Products Laboratory Ltd
Biotest UK
CSL Ltd
Grifols, S.A.
Johnson and Johnson
Kedrion S.p.A
Octapharma USA Inc
Taibang Biological Group Co. Ltd
Takeda Pharmaceutical Company Ltd

Reasons to Buy the Plasma Protein Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Plasma Protein Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Plasma Protein Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Plasma Protein Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Plasma Protein Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Plasma Protein Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Plasma Protein Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Plasma Protein Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Plasma Protein Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Plasma Protein Therapeutics Industry
4.2 Key Market Trends in Plasma Protein Therapeutics Industry
4.3 Potential Opportunities in Plasma Protein Therapeutics Industry
4.4 Key Challenges in Plasma Protein Therapeutics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Plasma Protein Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Plasma Protein Therapeutics Market Outlook by Segments
7.1 Plasma Protein Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

8 North America Plasma Protein Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Plasma Protein Therapeutics Markets in 2024
8.2 North America Plasma Protein Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Plasma Protein Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

9 Europe Plasma Protein Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Plasma Protein Therapeutics Markets in 2024
9.2 Europe Plasma Protein Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Plasma Protein Therapeutics Market Size Outlook by Segments, 2021-2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

10 Asia Pacific Plasma Protein Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Plasma Protein Therapeutics Markets in 2024
10.2 Asia Pacific Plasma Protein Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Plasma Protein Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

11 South America Plasma Protein Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Plasma Protein Therapeutics Markets in 2024
11.2 South America Plasma Protein Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Plasma Protein Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

12 Middle East and Africa Plasma Protein Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Plasma Protein Therapeutics Markets in 2024
12.2 Middle East and Africa Plasma Protein Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Plasma Protein Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ADMA Biologics Inc
Arthrex Inc
Baxter
Bio Products Laboratory Ltd
Biotest UK
CSL Ltd
Grifols, S.A.
Johnson and Johnson
Kedrion S.p.A
Octapharma USA Inc
Taibang Biological Group Co. Ltd
Takeda Pharmaceutical Company Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Albumin
Immunoglobulin
Plasma-derived factor VIII
Others
By Application
Hemophilia
Primary immunodeficiency disorder (PID)
Idiopathic thrombocytopenic purpura (ITP)
Others